Abstract

Octamer 4 (Oct-4), an important member of the POU domain transcription factor family, has been suggested to function as a master switch during differentiation of human somatic cells and more recently has come to be linked with neoplastic properties. The aim of this study was to evaluate the relationship between Oct-4 and cancer stage using a meta-analysis approach. Relevant articles published as of May 2015 were retrieved from the following databases: PubMed, ISI Web of Knowledge, Embase, and Chinese National Knowledge Infrastructure (CNKI). The strengths of relationship for outcomes of interest were estimated based on odds ratios (ORs) and 95% confidence intervals (CIs). A total of 11 articles on Oct-4 and cancer staging that collectively included 502 positive/high Oct-4 cases and 522 negative/low case-free controls were chosen. Positive/high Oct-4 was significantly associated with cancer stage in several kinds of cancer. Specifically, positive/high Oct-4 was associated with cancer stage III/IV (fixed effects: OR = 1.53, 95% CI = 1.12-2.10), primary tumor (T3-4) (random effects: OR = 1.93, 95% CI = 0.99-3.77), and cancer grade of differentiation (intermediate-poor) (random effects: OR = 3.45, 95% CI = 1.5-7.61). These findings suggest that positive/high Oct-4 is more strongly linked to stage III/IV cancer and cancer grade of differentiation, and is correlated with malignant characteristics that lead to poor prognosis in different types of cancer, especially in Asian. Given variability related to ethnicity and differences in cancer types, additional studies are warranted to establish the generalizability of our findings.

Highlights

  • Expression signature of the stemness state of primary tumors may represent a specific approach for identifying patients who are most likely to suffer recurrence or develop metastases. [1] the overexpression of several genes regulating stem cell properties has been documented in cancer tissues suggesting a possible prognostic role

  • Positive/high Octamer 4 (Oct-4) was associated with cancer stage III/IV, primary tumor (T3–4), and cancer grade of differentiation

  • These findings suggest that positive/high Oct-4 is more strongly linked to stage III/IV cancer and cancer grade of differentiation, and is correlated with malignant characteristics that lead to poor prognosis in different types of cancer, especially in Asian

Read more

Summary

Introduction

Expression signature of the stemness state of primary tumors may represent a specific approach for identifying patients who are most likely to suffer recurrence or develop metastases. [1] the overexpression of several genes regulating stem cell properties has been documented in cancer tissues suggesting a possible prognostic role. Positive/high nestin may be more strongly linked to advanced cancer stage and correlated with malignant characteristics that lead to poor prognosis in different cancers, especially lung cancer. Some subsequent studies of Oct-4 have reported a link between Oct-4 and malignant characteristics, and suggested that abundant Oct-4 expression correlates with greater malignancy and poor prognosis in different cancer types. Clarifying the contribution of Oct to malignant properties requires an evaluation of the relationship between Oct-4 and cancer stage. Octamer 4 (Oct-4), an important member of the POU domain transcription factor family, has been suggested to function as a master switch during differentiation of human somatic cells and more recently has come to be linked with neoplastic properties. The aim of this study was to evaluate the relationship between Oct-4 and cancer stage using a meta-analysis approach

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.